NFE2L2 and cancer: Preclinical data suggested that DPP-4i may promote the progression of pre-existing cancer, favouring metastatic spread, epithelial-mesenchymal transition (EMT) and activation of nuclear factor erythroid 2-related factor 2 (NRF2) [69].